Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).
The effect os SMS 201-995 (Sandostatin), a long-acting somatostatin analog, on different types of pituitary adenomas including alpha-subunit elevation is illustrated in this report. Treatment induced a fall in hCG levels in a woman with a pituitary adenoma producing only alpha-subunit. In 3 acromegalic patients, there was only a partial drop in GH and alpha-hCG. The same effect was observed in a woman with menopausal FSH and LH levels. SMS reduced plasma TSH and alpha-hCG in a case of thyrotropic adenoma. Two patients exhibiting FSH- and alpha-hCG-secreting adenomas did not respond to acute administration of SMS 201-995. More patients have to be treated before a definitive statement can be made on the usefulness of somatostatin analogs in the management of different types of pituitary adenomas.
Sassolas
G
G
Centre de Médecine Nucléaire, Hôpital Neuro-Cardiologique, Lyon, France.
Serusclat
P
P
Claustrat
B
B
Trouillas
J
J
Merabet
S
S
Cohen
R
R
Souquet
J C
JC
D000236:Adenoma / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D015292:Glycoprotein Hormones, alpha Subunit; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D015282:Octreotide; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood
D000970:Antineoplastic Agents; D015292:Glycoprotein Hormones, alpha Subunit; D010908:Pituitary Hormones, Anterior; D013004:Somatostatin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D015282:Octreotide